ATE275631T1 - Rekombinanter venezolanische-equine- pferdeenzephalitis-virusimpstoff - Google Patents

Rekombinanter venezolanische-equine- pferdeenzephalitis-virusimpstoff

Info

Publication number
ATE275631T1
ATE275631T1 AT99920967T AT99920967T ATE275631T1 AT E275631 T1 ATE275631 T1 AT E275631T1 AT 99920967 T AT99920967 T AT 99920967T AT 99920967 T AT99920967 T AT 99920967T AT E275631 T1 ATE275631 T1 AT E275631T1
Authority
AT
Austria
Prior art keywords
venezolan
equino
cephalitis
equine
recombinant
Prior art date
Application number
AT99920967T
Other languages
English (en)
Inventor
Alice Marie Bennett
Original Assignee
Secr Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Secr Defence filed Critical Secr Defence
Application granted granted Critical
Publication of ATE275631T1 publication Critical patent/ATE275631T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99920967T 1998-05-29 1999-05-05 Rekombinanter venezolanische-equine- pferdeenzephalitis-virusimpstoff ATE275631T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9811433A GB2337755B (en) 1998-05-29 1998-05-29 Virus vaccine
PCT/GB1999/001387 WO1999063098A1 (en) 1998-05-29 1999-05-05 Recombinant venezuelan equine encephalitis virus vaccine

Publications (1)

Publication Number Publication Date
ATE275631T1 true ATE275631T1 (de) 2004-09-15

Family

ID=10832820

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99920967T ATE275631T1 (de) 1998-05-29 1999-05-05 Rekombinanter venezolanische-equine- pferdeenzephalitis-virusimpstoff

Country Status (14)

Country Link
US (2) USRE41745E1 (de)
EP (1) EP1084261B8 (de)
AR (1) AR020080A1 (de)
AT (1) ATE275631T1 (de)
AU (1) AU3834999A (de)
BR (1) BR9910814A (de)
CA (1) CA2329133C (de)
DE (1) DE69920011T2 (de)
DK (1) DK1084261T3 (de)
ES (1) ES2224655T3 (de)
GB (1) GB2337755B (de)
MX (1) MXPA00011708A (de)
PT (1) PT1084261E (de)
WO (1) WO1999063098A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2337755B (en) 1998-05-29 2003-10-29 Secr Defence Virus vaccine
WO2002072754A2 (en) * 2001-03-08 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mva expressing modified hiv envelope, gag, and pol genes
US8623379B2 (en) 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
AU2002211948B2 (en) 2000-03-02 2007-09-13 Emory University DNA expression vectors and methods of use
EP1528677B1 (de) * 2003-10-30 2006-05-10 Agilent Technologies, Inc. Akustisch gekoppelter Dünnschicht-Transformator mit zwei piezoelektrischen Elementen, welche entgegengesetzte C-Axen Orientierung besitzten
RU2275937C1 (ru) * 2004-10-19 2006-05-10 Вирусологический центр НИИ Микробиологии Министерства обороны Российской Федерации Способ презентации вирусных антигенов иммунной системе хозяина, основанный на протеасомоопосредованной технологии, предназначенный для разработки методов биологической защиты
ES2439954T3 (es) 2007-02-23 2014-01-27 Her Majesty The Queen, In Right Of Canada, As Represented By The Minister Of National Defence Vectores víricos recombinantes para la prevención y la protección contra la infección por alfavirus
WO2010142017A1 (en) * 2009-06-09 2010-12-16 Defyrus, Inc . Administration of interferon for prophylaxis against or treatment of pathogenic infection
EP2675473A1 (de) 2011-02-15 2013-12-25 Immune Design Corp. Verfahren zur verbesserung von immunogenspezifischen immunreaktionen durch vektorisierte impfstoffe
EP3632463A1 (de) 2011-04-08 2020-04-08 Immune Design Corp. Immunogene zusammensetzungen und verfahren zur verwendung der zusammensetzungen zur induzierung humoraler und zellulärer immunreaktionen
US9555090B2 (en) 2012-04-04 2017-01-31 The United States of America as repesented by the Secretary of Army, on behalf of the U.S. Army Medical Research Institute of Infections Diseases Equine encephalitis virus vaccines and methods of using thereof
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccines for hsv-2
EP4389764B1 (de) * 2012-11-05 2026-03-18 Regeneron Pharmaceuticals, Inc. Genetisch modifizierte nagetiere und verfahren zur verwendung davon
EA035259B1 (ru) 2014-02-14 2020-05-21 Иммьюн Дизайн Корп. Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
US20170196954A1 (en) 2014-07-15 2017-07-13 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
HUE059343T2 (hu) 2016-01-29 2022-11-28 Bavarian Nordic As Rekombináns, módosított Ankara Vaccinia vírus (MVA) és ló encephalitis vírus oltóanyag
SG11201808457PA (en) 2016-04-15 2018-10-30 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
US11078282B2 (en) 2016-04-15 2021-08-03 Alpine Immune Sciences, Inc. CD80 variant immunomodulatory proteins and uses thereof
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
CN110088127A (zh) 2016-07-28 2019-08-02 高山免疫科学股份有限公司 Cd155变体免疫调节蛋白及其用途
WO2018170023A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
KR102692556B1 (ko) 2017-03-16 2024-08-09 알파인 이뮨 사이언시즈, 인코포레이티드 Pd-l1 변이체 면역조절 단백질 및 그의 용도
CN110662758A (zh) 2017-03-16 2020-01-07 高山免疫科学股份有限公司 Cd80变体免疫调节蛋白及其用途
CN110506060B (zh) 2017-03-30 2024-05-07 昆士兰大学 嵌合分子及其用途
EP3687561A4 (de) 2017-09-01 2021-06-09 The Australian National University Immunregulatorische moleküle und deren verwendung
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
PT3697810T (pt) 2017-10-18 2026-02-19 Alpine Immune Sciences Inc Proteínas imunomoduladoras de ligandos icos variantes e composições e métodos relacionados
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
KR20210089146A (ko) 2018-09-19 2021-07-15 알파인 이뮨 사이언시즈, 인코포레이티드 변이체 cd80 단백질 및 관련 구축물의 방법 및 용도
EP3887394A2 (de) 2018-11-30 2021-10-06 Alpine Immune Sciences, Inc. Cd86-variante immunmodulatorische proteine und verwendungen davon
JP2022529059A (ja) 2019-04-17 2022-06-16 アルパイン イミューン サイエンシズ インコーポレイテッド バリアントｉｃｏｓリガンド（ｉｃｏｓｌ）融合タンパク質の方法および使用
BR112022022524A2 (pt) 2020-05-08 2022-12-13 Alpine Immune Sciences Inc Proteínas imunomoduladoras inibidoras de april e baff com e sem uma proteína inibidora de células t e métodos de uso das mesmas
IL308336A (en) 2021-05-07 2024-01-01 Alpine Immune Sciences Inc Methods of dosing and treatment with TACI-FC modulatory fusion protein
US20250243260A1 (en) 2022-03-07 2025-07-31 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies and related methods and uses
JP2025535041A (ja) 2022-10-04 2025-10-22 アルパイン イミューン サイエンシズ インコーポレイテッド 自己抗体介在疾患の治療における使用のための変異ｔａｃｉ－ｆｃ融合タンパク質

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185440A (en) * 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
US5505947A (en) * 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US6261570B1 (en) * 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
GB2337755B (en) 1998-05-29 2003-10-29 Secr Defence Virus vaccine

Also Published As

Publication number Publication date
GB2337755A (en) 1999-12-01
GB9811433D0 (en) 1998-07-22
ES2224655T3 (es) 2005-03-01
DE69920011T2 (de) 2005-09-15
DK1084261T3 (da) 2005-01-17
BR9910814A (pt) 2001-02-13
PT1084261E (pt) 2005-01-31
GB2337755B (en) 2003-10-29
EP1084261B8 (de) 2004-12-15
AR020080A1 (es) 2002-04-10
EP1084261B1 (de) 2004-09-08
CA2329133A1 (en) 1999-12-09
WO1999063098A1 (en) 1999-12-09
CA2329133C (en) 2011-07-12
AU3834999A (en) 1999-12-20
EP1084261A1 (de) 2001-03-21
MXPA00011708A (es) 2005-10-13
DE69920011D1 (de) 2004-10-14
US6936257B1 (en) 2005-08-30
USRE41745E1 (en) 2010-09-21

Similar Documents

Publication Publication Date Title
ATE275631T1 (de) Rekombinanter venezolanische-equine- pferdeenzephalitis-virusimpstoff
NO20003303L (no) Vaksine
ATE287728T1 (de) Adjuvierte rekombinante lebendimpfstoffe gegen influenza- oder herpesviren
NO20014325D0 (no) Vaksine
DK0870508T3 (da) Influenzavaccine
NO20004758D0 (no) Vaksinesammensetning
NO20006191D0 (no) Vaksine
DK2251419T3 (da) Porcint reproduktions- og respirations-syndrom-vaccine baseret på isolat JA-142
DE69839169D1 (de) Aus infektiöser cDNA gewonnene rekombinate YF Viren-Impfstoffe
NO20020763D0 (no) Vaksine
NO20030239D0 (no) Modifisert virus
DE4192786T1 (de) Masernvirus-Rekombinanter Pockenvirus-Impfstoff
DK1923071T3 (da) Equint herpesvirusvaccine
ID26951A (id) Vaksin mycoplasma hyopneumontae recombinan
IS5777A (is) Bóluefnisvakið lifrarbólgu B veiruafbrigði og notkun þess
IS5694A (is) Bóluefni
ATE519775T1 (de) Rekombinante untereinheiten-impfstoffe
DK1248650T3 (da) Forbedrede DNA-vacciner til bovint herpesvirus 1
IS2797B (is) Bóluefni gegn ISA-veiru
HUP0002908A2 (en) Recombinant newcastle disease virus as embryo vaccine
DK1105498T3 (da) HIV vaccine
DK1325957T3 (da) Recombinant papilloma virus L1
ITMI981384A1 (it) Vaccino per hiv
PT841943E (pt) Virus herpeticos avirulentos uteis como agentes tumoricidas e vacinas
NO20002213D0 (no) Babesia vaksine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1084261

Country of ref document: EP